<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768686</url>
  </required_header>
  <id_info>
    <org_study_id>HM-CCRI-201</org_study_id>
    <secondary_id>KEYNOTE-B83</secondary_id>
    <secondary_id>MK3475-B83</secondary_id>
    <nct_id>NCT04768686</nct_id>
  </id_info>
  <brief_title>FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer</brief_title>
  <official_title>A Phase 2 Study to Assess the Safety, Efficacy of FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of&#xD;
      FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer.&#xD;
      This study is designed to assess the potential anti-tumor activity when administered at the&#xD;
      100mg QD of FLX475 with pembrolizumab and will be conducted (2) cohorts as detailed below.&#xD;
&#xD;
        -  Cohort 1: EBV negative / CPI naïve gastric cancer subjects who have progressed on at&#xD;
           least 2 prior systemic treatments for advanced or metastatic gastric cancer&#xD;
&#xD;
        -  Cohort 2: EBV positive / CPI naïve gastric cancer subjects who had at least 1 prior&#xD;
           systemic treatment for advanced or metastatic gastric cancer&#xD;
&#xD;
      Approximately 90 subjects may be enrolled across two cohorts to examine the safety and&#xD;
      efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate in subjects treated with FLX475 in combination with pembrolizumab</measure>
    <time_frame>Through study completion (approximately 2 years)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>FLX475 and pembrolizumab combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: EBV negative / CPI naïve gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer&#xD;
Cohort 2: EBV positive / CPI naïve gastric cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLX475</intervention_name>
    <description>tablet</description>
    <arm_group_label>FLX475 and pembrolizumab combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>FLX475 and pembrolizumab combination therapy</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must have histologically or cytologically confirmed, advanced, relapsed&#xD;
             or metastatic gastric or gastroesophageal junction adenocarcinoma&#xD;
&#xD;
          -  Patient must have one of the following diagnoses to be eligible for enrollment into&#xD;
             cohorts:&#xD;
&#xD;
               -  Cohort 1: Checkpoint inhibitor naïve Epstein-Barr Virus negative (EBV-) gastric&#xD;
                  cancer patient who has had a disease progression after at least 2 prior systemic&#xD;
                  treatments for advanced or metastatic gastric cancer&#xD;
&#xD;
               -  Cohort 2: Checkpoint inhibitor naïve Epstein-Barr virus positive (EBV+) gastric&#xD;
                  cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC)&#xD;
                  who had at least 1 prior systemic treatment for advanced or metastatic gastric&#xD;
                  cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1&#xD;
&#xD;
          -  Patient must have at least one measurable lesion at baseline by computed&#xD;
             tomography(CT) or magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Tumor available for biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed&#xD;
             to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137),&#xD;
             any history of discontinuing from that treatment due to Grade 3 or higher&#xD;
             immune-related adverse event (irAE)&#xD;
&#xD;
          -  Patient with MSI-H status&#xD;
&#xD;
          -  Active autoimmune disease or serious autoimmune disease within past 2 years requiring&#xD;
             systemic therapy&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, (non-infectious) pneumonitis that required&#xD;
             steroids, or clinical symptoms of active pneumonitis&#xD;
&#xD;
          -  Significant cardiovascular disease. New York Heart Association (NYHA) Class 3 or 4&#xD;
             congestive heart failure, or chronic Grade 3 hypertension.&#xD;
&#xD;
          -  Significant screening electrocardiogram (ECG) abnormalities&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eunkyoung Oh, Clinical Operation Director</last_name>
    <phone>+82 2 410 0370</phone>
    <email>eunkyoung.oh@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanllym University Medical Center</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent Hospital</name>
      <address>
        <city>Suwon-si,</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

